Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLight Life SciencesBLLSF 16 EV-to-OCF is -2.64 as of Aug. 04, 2026. GuruFocus rates BLLSF with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, BioLight Life Sciences ranks worse than 62.01% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioLight Life Sciences's Enterprise Value is $9.46 Mil.
BioLight Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.58 Mil. Therefore, BioLight Life Sciences's EV-to-OCF for today is -2.64.
The historical rank and industry rank for BioLight Life Sciences's EV-to-OCF or its related term are showing as below:
BLLSF'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.36 Med: -0.79 Max: 1.23
Current: -1.41
During the past 13 years, the highest EV-to-OCF of BioLight Life Sciences was 1.23. The lowest was -2.36. And the median was -0.79.
BLLSF's EV-to-OCF is ranked worse than 62.01% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs BLLSF: -1.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioLight Life Sciences (GREY:BLLSF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioLight Life Sciences's PE Ratio (TTM) for today is calculated as:
BioLight Life Sciences's share price for today is $0.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.432.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioLight Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLight Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioLight Life Sciences's EV-to-OCF falls into.
BioLight Life Sciences's current Enterprise Value is $9.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLight Life Sciences (BLLSF) has a EV-to-OCF of -2.64 as of Aug. 04, 2026. According to the industry distribution chart, BioLight Life Sciences ranks #875 out of 1411 companies in the Biotechnology industry, placing it in the top 62%.
Is BioLight Life Sciences' EV-to-OCF too high?
BioLight Life Sciences' current EV-to-OCF is -2.64. Based on the distribution chart, BioLight Life Sciences ranks #875 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLight Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLight Life Sciences ranks #875 out of 1411 companies for EV-to-OCF. This places BioLight Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioLight Life Sciences's current EV-to-OCF is -2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (BLLSF) has a current EV-to-OCF of -2.64. The current EV-to-OCF is -2.64. BioLight Life Sciences' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioLight Life Sciences (BLLSF), the current EV-to-OCF is -2.64 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score
Get the complete analysis for BLLSF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLSF has been successfully added to your 
